Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

US81578P1066
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG00HPLTRR8
SEER
Seer Inc
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Biotechnology · THEMEFOLIO: $HLTH
NAME
Seer Inc
ISIN
US81578P1066
TICKER
SEER
MIC
XNAS
REUTERS
SEER.OQ
BLOOMBERG
SEER US
Wed, 24.06.2026       Seer
US81578P1066

Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the “Radoff-JEC Group” or “we”), who collectively own approximately 7.7% of the outstanding shares of Seer, Inc. (NASDAQ: SEER) (“Seer” or the “Company”), today issued the following statement. This press release features multimedia. View the full release here: https:/...
Read more
Seer
Technical Analysis Termsheets Terminal
Permalink
Mon, 22.06.2026       Seer
US81578P1066

Findings from more than 5,500 plasma samples demonstrate the feasibility of combining deep plasma proteomics generated by the Proteograph Product Suite with ID-Free AI approaches across ten major cancer types Findings from more than 5,500 plasma samples demonstrate the feasibility of combining deep plasma proteomics generated by the Proteograph Pro...
Read more
Seer
Technical Analysis Termsheets Terminal
Permalink
Mon, 15.06.2026       Seer
US81578P1066

Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the “Radoff-JEC Group” or “we”), who collectively own approximately 7.7% of the outstanding shares of Seer, Inc. (NASDAQ: SEER) (“Seer” or the “Company”), today issued the following statement: This press release features multimedia. View the full release here: https:/...
Read more
Seer
Technical Analysis Termsheets Terminal
Permalink
Mon, 15.06.2026       Seer
US81578P1066

Urges Stockholders to Vote “FOR” ONLY Seer’s Director Nominees on the BLUE Proxy Card Urges Stockholders to Vote “FOR” ONLY Seer’s Director Nominees on the BLUE Proxy Card...
Read more
Seer
Technical Analysis Termsheets Terminal
Permalink
Wed, 03.06.2026       Seer
US81578P1066

Reinforces Seer’s Clear Strategy, Strong Governance and Significant Long-Term Value Creation Opportunity...
Read more
Seer
Technical Analysis Termsheets Terminal
Permalink
Fri, 29.05.2026       Seer
US81578P1066

Seeks Exclusion Order Barring Importation of Infringing Proteonano Kits and Workstations Seeks Exclusion Order Barring Importation of Infringing Proteonano Kits and Workstations...
Read more
Seer
Technical Analysis Termsheets Terminal
Permalink
Wed, 27.05.2026       Seer
US81578P1066

Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the “Radoff-JEC Group” or “we”), who collectively own approximately 7.8% of the outstanding shares of Seer, Inc. (NASDAQ: SEER) (“Seer” or the “Company”), today issued the following open letter to the Company’s independent directors and financial and legal advisors in...
Read more
Seer
Technical Analysis Termsheets Terminal
Permalink
Tue, 26.05.2026       Seer
US81578P1066

Seer to Showcase AI-Driven Multi-Cancer Screening Approach and Next-Generation Proteomics Capabilities at ASMS 2026...
Read more
Seer
Technical Analysis Termsheets Terminal
Permalink
Thu, 21.05.2026       Seer
US81578P1066

REDWOOD CITY, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that its Board of Directors (the “Board”) has thoroughly reviewed and unanimously rejected the further revised unsolicited non-binding proposal received on May 14, 2026, from Brad...
Read more
Seer
Technical Analysis Termsheets Terminal
Permalink
Thu, 14.05.2026       Seer
US81578P1066

Bradley L. Radoff and Michael Torok, who collectively own approximately 7.8% of the outstanding shares of Seer, Inc. (NASDAQ: SEER) (the “Company”), today submitted the following improved non-binding proposal to acquire the Company – their third such proposal – for $2.40 per share in cash plus a contingent value right. *** May 14, 2026 Seer,...
Read more
Seer
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Wed, 29.04.2026       Seer
US81578P1066

REDWOOD CITY, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that it will report financial results for the first quarter 2026 on Wednesday, May 13, 2026. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacif...
Read more
Seer
Technical Analysis Termsheets Terminal
Permalink
Wed, 29.04.2026       Seer
US81578P1066

Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the “Radoff-JEC Group” or “we”), who collectively own approximately 7.6% of the outstanding shares of Seer, Inc. (NASDAQ: SEER) (“Seer” or the “Company”), today issued the following statement in response to the Seer Board of Directors’ (the “Board”) rejection of the Ra...
Read more
Seer
Technical Analysis Termsheets Terminal
Permalink
Fri, 24.04.2026       Seer
US81578P1066

Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the “Radoff-JEC Group”), who collectively own approximately 7.6% of the outstanding shares of Seer, Inc. (NASDAQ: SEER) (“Seer” or the “Company”), today submitted the following improved non-binding proposal to acquire the Company for $2.35 per share in cash plus a cont...
Read more
Seer
Technical Analysis Termsheets Terminal
Permalink
Mon, 13.04.2026       Seer
US81578P1066

No Stockholder Action Required at This Time No Stockholder Action Required at This Time...
Read more
Seer
Technical Analysis Termsheets Terminal
Permalink
Mon, 13.04.2026       Seer
US81578P1066

Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the “Radoff-JEC Group”), who collectively own approximately 7.6% of the outstanding shares of Seer, Inc. (NASDAQ: SEER) (“Seer” or the “Company”), today submitted the following non-binding proposal to acquire the Company for $2.25 per share in cash plus a contingent va...
Read more
Seer
Technical Analysis Termsheets Terminal
Permalink
Thu, 09.04.2026       Seer
US81578P1066

Seer’s Proteograph will be used to generate enhanced proteomic insights in one of the world’s largest multi-omic health studies Seer’s Proteograph will be used to generate enhanced proteomic insights in one of the world’s largest multi-omic health studies...
Read more
Seer
Technical Analysis Termsheets Terminal
Permalink
Mon, 30.03.2026       Seer
US81578P1066

23 claims of U.S. Patent No. 11,435,360 remain valid, supporting Seer's Proteograph® Product Suite 23 claims of U.S. Patent No. 11,435,360 remain valid, supporting Seer's Proteograph® Product Suite...
Read more
Seer
Technical Analysis Termsheets Terminal
Permalink
Wed, 04.03.2026       Seer
US81578P1066

Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the “Radoff-JEC Group”), who collectively own approximately 7.6% of the outstanding common stock of Seer, Inc. (NASDAQ: SEER), today issued the following open letter to independent directors Meeta Gulyani and Nicolas Roelofs. *** March 4, 2026 Seer, Inc. 3800 Bri...
Read more
Seer
Technical Analysis Termsheets Terminal
Permalink
Thu, 26.02.2026       Seer
US81578P1066

REDWOOD CITY, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that its Board of Directors unanimously adopted a tax benefit preservation plan (“NOL Plan”) designed to help preserve and protect Seer’s valuable income tax net operating loss c...
Read more
Seer
Technical Analysis Termsheets Terminal
Permalink
Thu, 26.02.2026       Seer
US81578P1066

REDWOOD CITY, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today reported financial results for the fourth quarter and full year ended December 31, 2025....
Read more
Seer
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Mon, 23.02.2026       Seer
US81578P1066

Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the “Radoff-JEC Group”), who collectively own nearly 7.5% of the outstanding common stock of Seer, Inc. (NASDAQ: SEER) (“Seer” or the “Company”), today issued the following open letter to the Company’s Board of Directors. *** February 23, 2026 Seer, Inc. 3800 Bri...
Read more
Seer
Technical Analysis Termsheets Terminal
Permalink
Thu, 19.02.2026       Seer
US81578P1066

Nathan Basisty, Sasha Singh, Bruce Wilcox, and Mozhgan Boroumand among scientific leaders presenting unique proteomics-enabled biological insights Nathan Basisty, Sasha Singh, Bruce Wilcox, and Mozhgan Boroumand among scientific leaders presenting unique proteomics-enabled biological insights...
Read more
Seer
Technical Analysis Termsheets Terminal
Permalink
Mon, 01.12.2025       Seer
US81578P1066

Large-scale GWAS across ~1,600 samples shows how peptide-level mass spectrometry distinguishes true protein changes from potential binding artifacts resulting from affinity-based approaches, establishing accuracy as the foundation for downstream discovery Large-scale GWAS across ~1,600 samples shows how peptide-level mass spectrometry distinguishes...
Read more
Seer
Technical Analysis Termsheets Terminal
Permalink
Fri, 07.11.2025       Seer
US81578P1066

Studies spanning cardiovascular, aging, and cancer biology highlight how Seer’s Proteograph® platform is enabling discovery at population scale Studies spanning cardiovascular, aging, and cancer biology highlight how Seer’s Proteograph® platform is enabling discovery at population scale...
Read more
Seer
Technical Analysis Termsheets Terminal
Permalink
Thu, 06.11.2025       Seer
US81578P1066

REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today reported financial results for the third quarter ended September 30, 2025....
Read more
Seer
Technical Analysis Termsheets Terminal
Permalink
Thu, 16.10.2025       Seer
US81578P1066

REDWOOD CITY, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that it will report financial results for the third quarter 2025 on Thursday, November 6, 2025. Company management will be webcasting a conference call beginning at 1:30 p.m. Pac...
Read more
Seer
Technical Analysis Termsheets Terminal
Permalink
Fri, 10.10.2025       Seer
US81578P1066

Scientific presentations reveal how Seer’s Proteograph Product Suite is a critical component of multi-omic translational studies and enables profiling of protein isoform-specific biomarkers Scientific presentations reveal how Seer’s Proteograph Product Suite is a critical component of multi-omic translational studies and enables profiling of protei...
Read more
Seer
Technical Analysis Termsheets Terminal
Permalink
Tue, 26.08.2025       Seer
US81578P1066

REDWOOD CITY, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that the company will be participating in the upcoming Morgan Stanley 23rd Annual Global Healthcare Conference in New York, NY....
Read more
Seer
Technical Analysis Termsheets Terminal
Permalink
Thu, 31.07.2025       Seer
US81578P1066

REDWOOD CITY, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that the company will be participating in the upcoming Canaccord Genuity 45th Annual Growth Conference in Boston, MA....
Read more
Seer
Technical Analysis Termsheets Terminal
Permalink
Sun, 01.06.2025       Seer
US81578P1066

First-of-its-kind study will use Seer’s next-generation workflow to identify early-onset cancer biomarkers and power deep, unbiased mass spectrometry-based proteomics...
Read more
Seer
Technical Analysis Termsheets Terminal
Permalink
Thu, 29.05.2025       Seer
US81578P1066

REDWOOD CITY, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced the launch of its new Proteograph® Product Suite, featuring the Proteograph ONE Assay and SP200 Automation Instrument—its most advanced solution yet for scalable, high-resolution,...
Read more
Seer
Technical Analysis Termsheets Terminal
Permalink
Tue, 13.05.2025       Seer
US81578P1066

Revenue grew 37%, driven by increased product sales and service revenue Revenue grew 37%, driven by increased product sales and service revenue...
Read more
Seer
Technical Analysis Termsheets Terminal
Permalink
Fri, 21.02.2025       Seer
US81578P1066

REDWOOD CITY, Calif., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating in the upcoming TD Cowen 45th Annual Healthcare Conference in Boston, MA....
Read more
Seer
Technical Analysis Termsheets Terminal
Permalink
Thu, 13.02.2025       Seer
US81578P1066

REDWOOD CITY, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the fourth quarter and full year 2024 on Thursday, February 27, 2025. Company management will be webcasting a confere...
Read more
Seer
Technical Analysis Termsheets Terminal
Permalink
Fri, 08.11.2024       Seer
US81578P1066

REDWOOD CITY, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced company management will be participating in the following investor conferences:...
Read more
Seer
Technical Analysis Termsheets Terminal
Permalink
Thu, 31.10.2024       Seer
US81578P1066

CoLab session with PrognomiQ and Salk Institute plus multiple presentations of new data offer firsthand look at multi-omic breakthroughs powered by Seer’s Proteograph™ Product Suite CoLab session with PrognomiQ and Salk Institute plus multiple presentations of new data offer firsthand look at multi-omic breakthroughs powered by Seer’s Proteograph™...
Read more
Seer
Technical Analysis Termsheets Terminal
Permalink
Thu, 22.08.2024       Seer
US81578P1066

REDWOOD CITY, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating in the upcoming Morgan Stanley 22nd Annual Global Healthcare Conference in New York, NY....
Read more
Seer
Technical Analysis Termsheets Terminal
Permalink
Fri, 09.08.2024       Seer
US81578P1066

REDWOOD CITY, Calif., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating in the upcoming Canaccord Genuity 44th Annual Growth Conference in Boston, MA....
Read more
Seer
Technical Analysis Termsheets Terminal
Permalink
Tue, 11.06.2024       Seer
US81578P1066

Secretome profiles from SpaceX Inspiration4 mission show alterations in oxidative stress, brain homeostasis, and coagulation...
Read more
Seer
Technical Analysis Termsheets Terminal
Permalink
Sun, 02.06.2024       Seer
US81578P1066

Combined Workflow of Proteograph™ XT Assay and Thermo Scientific™ Orbitrap™ Astral™ Mass Spectrometer Robustly Identifies over 13,000 Protein Groups Across a Study of 2,840 Subjects Combined Workflow of Proteograph™ XT Assay and Thermo Scientific™ Orbitrap™ Astral™ Mass Spectrometer Robustly Identifies over 13,000 Protein Groups Across a Study of 2...
Read more
Seer
Technical Analysis Termsheets Terminal
Permalink
Sat, 02.04.2022       Seer
US81578P1066

New York, New York--(Newsfile Corp. - April 1, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Seer, Inc. (NASDAQ: SEER) resulting from allegations that Seer may have issued materially misleading business information to the investing public.SO WH...
Read more
Seer
Technical Analysis Termsheets Terminal
Permalink
Sat, 04.12.2021       Seer
US81578P1066

Los Angeles, California--(Newsfile Corp. - December 3, 2021) -  The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Seer, Inc. ("Seer" or "the Company") (NASDAQ: SEER) for violations of the securities laws.The investigation focuses on whether the Company issued...
Read more
Seer
Technical Analysis Termsheets Terminal
Permalink
Wed, 24.11.2021       Seer
US81578P1066

Los Angeles, California--(Newsfile Corp. - November 23, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Seer, Inc. ("Seer" or "the Company") (NASDAQ: SEER) for violations of the securities laws.The investigation focuses on whether the Company issued fals...
Read more
Seer
Technical Analysis Termsheets Terminal
Permalink
Mon, 22.11.2021       Seer
US81578P1066

Los Angeles, California--(Newsfile Corp. - November 22, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Seer, Inc. ("Seer" or "the Company") (NASDAQ: SEER) for violations of the securities laws.The investigation focuses on whether the Company issued fals...
Read more
Seer
Technical Analysis Termsheets Terminal
Permalink
Mon, 15.11.2021       Seer
US81578P1066

Los Angeles, California--(Newsfile Corp. - November 15, 2021) -  The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Seer, Inc. ("Seer" or "the Company") (NASDAQ: SEER) for violations of the securities laws.The investigation focuses on whether the Company issue...
Read more
Seer
Technical Analysis Termsheets Terminal
Permalink
Wed, 10.11.2021       Seer
US81578P1066

Los Angeles, California--(Newsfile Corp. - November 10, 2021) -  The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Seer, Inc. ("Seer" or "the Company") (NASDAQ: SEER) for violations of the securities laws.The investigation focuses on whether the Company issue...
Read more
Seer
Technical Analysis Termsheets Terminal
Permalink
Wed, 10.11.2021       Seer
US81578P1066

Boston, Massachusetts--(Newsfile Corp. - November 10, 2021) - Block & Leviton is investigating Seer, Inc. (NASDAQ: SEER) for potential securities law violations. Investors who have lost money in their Seer investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://www.blockleviton...
Read more
Seer
Technical Analysis Termsheets Terminal
Permalink
Mon, 08.11.2021       Seer
US81578P1066

Los Angeles, California--(Newsfile Corp. - November 8, 2021) -  The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Seer, Inc. ("Seer" or "the Company") (NASDAQ: SEER) for violations of the securities laws.The investigation focuses on whether the Company issued...
Read more
Seer
Technical Analysis Termsheets Terminal
Permalink
Mon, 08.11.2021       Seer
US81578P1066

Boston, Massachusetts--(Newsfile Corp. - November 8, 2021) - Block & Leviton is investigating Seer, Inc. (NASDAQ: SEER) for potential securities law violations. Investors who have lost money in their Seer investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://www.blockleviton....
Read more
Seer
Technical Analysis Termsheets Terminal
Permalink
Fri, 05.11.2021       Seer
US81578P1066

Atlanta, Georgia--(Newsfile Corp. - November 5, 2021) - Holzer & Holzer, LLC is investigating whether Seer, Inc. ("Seer" or the "Company") (NASDAQ: SEER) complied with federal securities laws. On November 4, 2021, Seeking Alpha published a report entitled "Seer Inc. falls after new short call from The Bear Cave." According to Seeking Alpha, The...
Read more
Seer
Technical Analysis Termsheets Terminal
Permalink